Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation

被引:0
|
作者
Ymir Saemundsson
Signý Vala Sveinsdottir
Henrik Svantesson
Peter J. Svensson
机构
[1] Lund University,Department for Coagulation Disorders
[2] Centre for Thrombosis and Haemostasis,undefined
[3] Skåne University Hospital,undefined
[4] Kungälv Hospital,undefined
来源
关键词
Homozygous factor V Leiden; APC-resistance; Thrombosis; Venous thromboembolism; Thrombophilia; Heterozygous prothrombin mutation;
D O I
暂无
中图分类号
学科分类号
摘要
The most common forms of familial thrombophilia are factor V Leiden (FVL) and prothrombin mutation (PTM). Homozygous FVL and PTM have long been feared conditions thought to cause high rates of morbidity and mortality. To analyse clinical features in patients with homozygous FVL and PTM, as well as patients with double heterozygosity for FVL and PTM. All patients with homozygous FVL, PTM or double heterozygosity in the MATS database of 1465 consecutive unselected patients were analysed regarding age at inclusion venous thromboembolism (VTE), age at first thrombosis, recurrence, clinical course and acquired risk factors. We found 36 patients homozygous for FVL. Patients homozygous for FVL were younger than controls at group level (56 ± 18 vs. 63 ± 17, p < 0.02). Homozygous women were younger than female controls (50 ± 19 vs. 63 ± 18, p < 0.002). No difference was observed when comparing male subjects. Women were younger than men at inclusion thrombosis (50 ± 19 vs. 65 ± 14, p < 0.02) and at first thrombosis (47 ± 19 vs. 64 ± 14, p < 0.01). Deep venous thrombosis (DVT) was seen in 33 patients (92 %), 6 (17 %) had pulmonary embolism (PE) and 3 (8 %) had combined DVT and PE. PE was less frequent in homozygous FVL women compared to female controls (p < 0.03). VTE recurred in 3 subjects during the duration of the study. Odds ratio for VTE in homozygous FVL patients compared to controls was 13.9 (95 % CI 9.9–19.7). We found no subjects with homozygous PTM. Double heterozygosity for FVL and PTM was seen in 12 subjects. There was no difference in age at inclusion VTE between double heterozygotes and controls (59 ± 16 vs. 63 ± 17, ns.). DVT was seen in 92 % at inclusion, 8 % had PE. Mean age at first VTE was 52 ± 17 (27–82). Consecutive homozygous FVL patients had a higher age at first thrombosis than previously described. Homozygous females are affected at an earlier age than homozygous men and female controls. It seems that thrombi in homozygous FVL have a different pattern compared to controls i.e. more prone for thrombosis in the lower extremity. The odds ratio for thrombosis among homozygous FVL seems to be lower than previously described.
引用
收藏
页码:324 / 331
页数:7
相关论文
共 50 条
  • [1] Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation
    Saemundsson, Ymir
    Sveinsdottir, Signy Vala
    Svantesson, Henrik
    Svensson, Peter J.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (03) : 324 - 331
  • [2] Homozygous factor V Leiden and compound heterozygosity for factor V Leiden and prothrombin mutation
    Saemundsson, Y.
    Sveinsdottir, S., V
    Svantesson, H.
    Svensson, P. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 151 - 151
  • [3] Factor V Leiden and prothrombin gene mutation
    Björkman, A
    Svensson, PJ
    Hillarp, A
    Burtscher, IM
    Rünow, A
    Benoni, G
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2004, (425) : 168 - 172
  • [4] Compound heterozygosity for factor V Leiden and factor V deficiency resulting in phenotypic homozygosity for factor V Leiden.
    Jain, M
    Zehnder, JL
    [J]. BLOOD, 1995, 86 (10) : 3656 - 3656
  • [5] Frequency of factor V Leiden and prothrombin mutation in tested samples for thrombophilia and concordance of functional and molecular tests for factor V Leiden mutation
    Alshaikh, A.
    Owaidah, T.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 620 - 621
  • [6] Homozygous Factor V Leiden mutation in sickle cell anaemia
    Kordes, U
    Janka-Schaub, G
    Kulozik, A
    Schneppenheim, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (01) : 236 - 236
  • [7] Impact of double heterozygosity for Factor V Leiden and Prothrombin G20210A on the thrombotic phenotype
    Luxembourg, Beate
    Henke, Franziska
    Kirsch-Altena, Anette
    Sachs, Ulrich
    Kemkes-Matthes, Bettina
    [J]. THROMBOSIS RESEARCH, 2021, 200 : 121 - 127
  • [8] Factor v Leiden mutation and preeclampsia
    Rigó, J
    Nagy, B
    Fintor, L
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (04) : 853 - 853
  • [9] Tamoxifen and the Factor V Leiden Mutation
    Cuzick, Jack
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (13) : 918 - U1
  • [10] The distribution of Factor V Leiden mutation
    Eroglu, Aydan
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (03) : 341 - 342